Celgene In Licensing "Discussions" On Thalomid Risk Management Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Thalidomide STEPS program patents and increasing emphasis on restricted drug distribution systems create "potential licensing and revenue opportunities," Celgene says. The patents are blocking implementation of revised risk management plans for Accutane and isotretinoin generics.
You may also be interested in...
Allergan To Discuss Tazoral Psoriasis Non-Inferiority Study With FDA
FDA deems oral tazarotene "not approvable." In addition to a non-inferiority study, Allergan must develop an "acceptable" risk management program and resolve manufacturing problems.
Allergan To Discuss Tazoral Psoriasis Non-Inferiority Study With FDA
FDA deems oral tazarotene "not approvable." In addition to a non-inferiority study, Allergan must develop an "acceptable" risk management program and resolve manufacturing problems.
Revised Accutane Label Describes Lack Of PK Effect On Ortho-Novum
A study of 31 women showed Accutane at the recommended dose did not induce clinically relevant changes in the pharmacokinetics of the oral contraceptive. Accutane's "black box" warning concerning possible interactions between isotretinoin and oral contraceptives remains in labeling.